Human
Intact FGF-21 ELISA Kit
Description
This
sandwich ELISA (enzyme-linked immunosorbent assay) kit is intended for the
quantitative determination of human intact FGF-21 levels in EDTA-plasma or
serum. This assay does not detect human FGF-21 fragments.
For
research use only. Not for use in diagnostics procedures.
Background
Fibroblast
growth factor 21 (FGF-21) belongs to the FGF-19 subfamily, which includes
FGF-19, FGF-21, and FGF-23. The FGF-19 family members are potent endocrine
hormones in the regulation of a diverse physiological homeostasis.
The
intact FGF-21 is a small protein comprising of 181 amino acids. Administration
of recombinant FGF-21 lowered plasma glucose and insulin levels, reduced
hepatic and circulating triglyceride and cholesterol levels, and improved
insulin sensitivity, energy expenditure, hepatic steatosis, and obesity in a
range of insulin-resistant animal models. The physiological functions of FGF-21
rely on the intact molecular structure and animno
acid sequence in its N-terminal and C-terminal region. An N-terminal-truncated
FGF-21 (7-181) is a potent inhibitor that competitively inhibits the biological
activity of intact FGF-21 (1-181). Therefor, it is important to measure the
amount of circulating, intact FGF-21 levels in the assessment of physiological
and pathophysiological condition. An assay that determines FGF-21 fragments may
overestimate the biological activity of the protein in test samples.
Circulating
FGF-21 is a biomarker and its levels are increased in patients with
nonalcoholic fatty liver disease (NAFLD), type 2 diabetes, gestational
diabetes, and obesity. An increase of circulating FGF-21 is also found in
patients with Cushing's syndrome and patients with lipodystrophy induced by
HIV-1, as well as those with chronic renal disease or end-stage renal disease
(ESRD).
For research use only. Not for use in
diagnostics procedures.
(주)엘바이오시스템은 EDI(EPITOPE DIAGNOSTICS, INC)의 한국공식대리점입니다.
제품의 주문 및 관련정보가 필요하시면 전화, 이메일로 문의해 주세요.